Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond measuring gene sequence to measuring gene function, Function Oncology aims to identify optimal therapeutic opportunities for patients and advance the next generation of targeted cancer therapies.
Function Oncology’s functional genomics platform leverages CRISPR-based gene modulation directly in patient clinical samples, enabling personalized, comprehensive profiling of each patients’ tumors to uncover drug target dependencies that cannot be fully identified by conventional genomic profiling. These patient-specific insights may be used to produce tailored treatment strategies and in aggregate could both power the development of new therapies against known or novel cancer drivers.
The platform that has potential for both diagnostic and therapeutic clinical applications. These applications range from accelerating target identification and validation, to producing unprecedented insights to enroll the right patients in clinical trials, to expanding the impact of existing drugs and surfacing novel cancer targets for drug development.
The company launched in 2023 with $28 Million in Series A funding.